StonkScan
OverviewRevenueFinancialsValuationOutlookOwnership
Price
Performance · vs S&P 500
Company
Medtronic plc
NYSE · USD
Large cap
0.90× peer median
1.13× peer median
43% less volatile
Claude reads this page's data and writes up Medtronic plc's financials, valuation and analyst coverage: built only from the figures here, with nothing pulled in from elsewhere.
Generated by an AI model from the data on this page. It can be wrong, and it isn't investment advice or a recommendation to buy or sell anything. Check every figure against the sections themselves before you rely on it.
$18.7B of net debt against $7.3B of annual operating cash flow.
Liquidity · FY26
$31.7B in FY22 to $36.4B in FY26, with the latest year up 8.4%.
Growth · FY26
18.2% in FY22 to 17.8% in FY26.
Profitability · FY26
Free cash flow of $5.4B covers the business without outside capital, on $9.2B of cash and short-term investments.
Liquidity · FY26
$24.8B of current assets against $11.7B due within a year.
Liquidity · FY26
$36.4B of revenue against $29.9B of operating costs, leaving $6.5B.
Profitability · FY26
$26.4B of free cash flow against $21.9B of net income across 5 fiscal years.
Quality · FY26
Revenue came in above consensus by 1.6% on average over the last four reports.
Quality · Sep '26
Medtronic's growth is accelerating again as its cardiovascular business expands. It's about to become a Dividend King, and its stock still looks like a bargain.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Medtronic raises its fiscal 2027 outlook as growth broadens across major franchises and newer platforms, with robotics and ablation investments advancing.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Medtronic PLC (NYSE:MDT) on Tuesday reported better-than-expected first-quarter financial results and raised its FY27 adjusted EPS guidance.
/PRNewswire/ -- Společnost Cornerstone Robotics, inovativní firma zabývající se chirurgickou robotikou, která byla založena v Hongkongu a má tam také své
Average month-end to month-end move for MDTin each calendar month. Point at a bar for that month's spread: past seasonality is a tendency in a small sample, not a forecast.
+$2.8B vs FY25
FY25 → FY26
FY22 → FY26, annualized
+9.8% vs the four before
Q1 FY27 · +13.7% YoY
Share of the latest fiscal year, largest first. The line is the segment across every fiscal year we have: hover it to read one.
What each segment added to or took off the top line in dollars: ranked by the size of the move, not its percentage.
+8.4% YoY
−0.3 pp YoY
+0.0 pp YoY
+3.0% YoY
−0.7 pp YoY
+3.3% YoY
+4.6% YoY
+$812M YoY
| $ billions | FY26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| Cash & equivalents | 1.9 | 2.2 | 1.3 | 1.5 | 3.7 |
| Short-term investments | 7.3 | 6.7 | 6.7 | 6.4 | 6.9 |
| Receivables | 6.6 | 6.5 | 6.1 | 6.0 | 5.6 |
| $ billions | FY26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| Operating cash flow | 7.3 | 7.0 | 6.8 | 6.0 | 7.3 |
| Capital expenditure | −1.9 | −1.9 | −1.6 | −1.5 | −1.4 |
| Free cash flow | 5.4 | 5.2 | 5.2 |
P/E vs EPS growth · below the channel = cheaper for its growth
P/S vs revenue growth · below the channel = cheaper for its growth
| Ticker | P/E | Fwd P/E | PEG | P/S | Fwd P/S | PSG | EPS gr | Rev gr |
|---|---|---|---|---|---|---|---|---|
| MDT | 22.8 | 15.6 | 0.69 | 3.2 | 3.1 | 0.60 | 23% | 5% |
| VRTX | 32.2 | 29.8 | 1.66 | 11.2 | 10.7 | 1.00 | 18% | 11% |
| BMY | 15.0 | 9.8 | 0.56 | 2.8 | 2.8 | - | 18% | -5% |
| CVS | 25.4 | 12.2 | 0.13 | 0.3 | 0.3 | 0.08 | 91% | 4% |
| SYK | 31.7 | 20.5 | 0.68 | 4.6 | 4.3 | 0.51 | 30% | 8% |
| MCK | 24.6 | 20.7 | 1.44 | 0.3 | 0.2 | 0.03 | 14% | 7% |
Dots = reported EPS vs consensus · gap = surprise · dashed = estimate ($)
Solid = reported · dashed = forward consensus · shaded = analyst low–high ($B)
Rows: discount rate (r) · Columns: terminal growth (g∞) · cell = fair value, shaded by up/downside vs 93.
Last 12M · $85M bought · $14M sold · net +$71M
| Inventory |
|---|
| 6.0 |
| 5.5 |
| 5.2 |
| 5.3 |
| 4.6 |
| Total current assets | 24.8 | 23.8 | 21.9 | 21.7 | 23.1 |
|---|
| Property, plant & equipment | 7.4 | 6.8 | 6.1 | 5.6 | 5.4 |
|---|
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
|---|
| Other non-current assets | 60.8 | 61.0 | 61.9 | 63.7 | 62.5 |
|---|
| Total assets | 93.0 | 91.7 | 90.0 | 90.9 | 91.0 |
|---|
| Accounts payable | 2.6 | 2.4 | 2.4 | 2.7 | 2.3 |
|---|
| Short-term debt | 1.8 | 2.9 | 1.1 | 0.0 | 3.7 |
|---|
| Total current liabilities | 11.7 | 12.9 | 10.8 | 9.1 | 12.4 |
|---|
| Long-term debt | 26.1 | 25.6 | 23.9 | 24.3 | 20.3 |
|---|
| Total liabilities | 43.0 | 43.4 | 39.6 | 39.3 | 38.3 |
|---|
| Shareholders’ equity | 49.5 | 48.0 | 50.2 | 51.5 | 52.6 |
|---|
Fiscal year · latest five reported years
| 4.6 |
| 6.0 |
| Investing cash flow | −2.9 | −1.9 | −2.4 | −3.5 | −1.7 |
|---|
| Dividends paid | −3.6 | −3.6 | −3.7 | −3.6 | −3.4 |
|---|
| Share buybacks | −1.0 | −3.2 | −2.1 | −0.6 | −2.5 |
|---|
| Net debt issued / (repaid) | −1.2 | 2.1 | 1.1 | −0.6 | −0.0 |
|---|
| Financing cash flow | −4.8 | −4.4 | −4.5 | −5.0 | −5.3 |
|---|
| Net change in cash | −0.3 | 0.9 | −0.3 | −2.2 | 0.1 |
|---|
Fiscal year · outflows shown negative